CLL: ibrutinib yields favorable outcomes across treatment lines

  • O'Brien SM & al.
  • Am J Hematol
  • 14 feb. 2019

  • de David Reilly
  • Univadis Clinical Summaries
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • In patients with chronic lymphocytic leukemia (CLL), ibrutinib delivered favorable response and survival outcomes across treatment lines.
  • Among patients who discontinued ibrutinib, those receiving ibrutinib in earlier treatment lines experienced better survival outcomes.  

Why this matters

  • Ibrutinib discontinuation has been associated with inferior survival in patients with high-risk CLL who have experienced multiple relapses.

Study design

  • Study to investigate outcomes with ibrutinib for CLL by treatment line or discontinuation/after discontinuation.
  • Data sources:
    • RESONATE study (n=135) in patients aged ≥65 years with treatment-naive disease.
    • RESONATE 2 study (n=136) in patients who had received ≥1 prior therapy.
  • Funding: Pharmacyclics LLC, an AbbVie Company.

Key results

  • Median PFS and OS were not reached regardless of number of prior lines of therapy.
  • Overall response rate (ORR):
    • 0 prior therapies: 92%.
    • 1-2 prior therapies: 96%.
    • ≥3 prior therapies: 88%.
  • 3.7% of treatment-naive patients and 20% of relapsed/refractory patients discontinued ibrutinib because of progressive disease (PD).
  • Median OS after discontinuation:
    • 0 prior therapies: NR (95% CI, 5.9 months-not estimable [NE]).
    • 1-2 prior therapies: 9.3 (95% CI, 7.8-22) months.
    • ≥3 prior therapies: 8.9 (95% CI, 4.3-NE) months.

Limitations

  • Retrospective data.